Jefferson Health Plans

2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Evrysdi

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: □ Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	**Specialty/facility name (if applicable):**

☐ REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is the medication prescribed by or in consultation with a neurologist or physician who specializes in treatment of spinal muscular atrophy?

☐ Yes ☐ No

Q2. Does the member have a diagnosis of spinal muscular atrophy type I, II, or III?

☐ Yes ☐ No

Q3. Is the patient's diagnosis of spinal muscular atrophy confirmed by the following?

☐ Laboratory documentation of homozygous deletion or mutation of SMN 1 gene

Q4. Does the prescribed dose follow the recommended dosing per Evrysdi™ (risdiplam) prescribing information as described below?

☐ If under 2 months of age, dose does not exceed 0.15 mg/kg per day

☐ If 2 months of age to less than 2 years of age, dose does not exceed 0.2 mg/kg per day

☐ If 2 years of age and older, weighing less than 20 kg, dose does not exceed 0.25 mg/kg per day

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Jefferson Health Plans

2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Evrysdi

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**

☐ If 2 years of age and older, weighing 20 kg or more, dose does not exceed 5 mg per day

Q5. Does the patient meet at least one of the following criteria?

☐ Member is not concurrently being treated with gene therapy, including Spinraza® and/or Zolgensma®, or currently enrolled in a clinical trial to receive gene therapy for SMA

☐ Member previously received gene therapy and was unable to maintain beneficial response in SMA-associated symptoms as documented by chart notes

Q6. Does the patient receive comprehensive treatment based on standards of care for spinal muscular dystrophy?

☐ Yes ☐ No

Q7. For renewal: Is the medication prescribed by or in consultation with a neurologist or physician who specializes in treatment of spinal muscular atrophy?

☐ Yes ☐ No

Q8. Does the patient continue to meet the diagnostic criteria?

☐ Yes ☐ No

Q9. Is the patient receiving clinical benefit based on the prescriber's assessment?

☐ Yes ☐ No

Q10. Does the patient receive comprehensive treatment based on standards of care for spinal muscular dystrophy?

☐ Yes ☐ No

Q11. Does the prescribed dose follow the recommended dosing per Evrysdi™ (risdiplam) prescribing information as described below?

☐ If under 2 months of age, dose does not exceed 0.15 mg/kg per day
☐ If 2 months of age to less than 2 years of age, dose does not exceed 0.2 mg/kg per day

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Jefferson Health Plans

2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Evrysdi

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**

☐ If 2 years of age and older, weighing less than 20 kg, dose does not exceed 0.25 mg/kg per day

☐ If 2 years of age and older, weighing 20 kg or more, dose does not exceed 5 mg per day

Q12. Does the patient have the absence of unacceptable toxicity which precludes safe administration of the drug?

☐ Yes ☐ No

Q13. Additional Information:

_____ _____

Prescriber Signature Date

2024 Prior Authorization Request

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document